Editorial

Exploring the Societal Impact of Antimicrobial Resistance

Kalpana Singh[*]

Antimicrobial resistance (AMR) tends to be one of the greatest threats to health, economies, and sustainable development in the twenty-first century globally. This editorial looks at the wide-reaching effects of AMR, focusing on how it impacts public health, healthcare systems, and economic stability. AMR contributes to increasing the inequality gap between low and middle-income countries, further reducing the efficacy of medical treatments, thereby exacerbating sickness, mortality, and treatment costs. By 2050, AMR could cause a global economic retraction of up to 3.8%. MR also threatens progress on United Nations Sustainable Development Goals (SDGs), such as good health (SDG 3) and Pro-economic growth (SDG 8).

This editorial emphasizes innovative solutions, including improved antibiotic stewardship, quicker diagnostic methods, alternative therapies, and policy recommendations for a unified global approach. Antibiotic overuse in agriculture and animal husbandry has significantly contributed to human AMR development and spread in humans. Investing in the development of new antibiotics, helpful research, and alternative therapies is crucial to avoid resistant pathogens. International coordination for equitable access to lifesaving treatments is necessary to prevent the spread of life-threatening resistant infections. This editorial discusses evidence-based strategies, including antimicrobial stewardship (AMS), faster diagnostics, and alternative treatments, alongside policy ideas for coordinated global action. Addressing overuse in agriculture and investing in new antibiotics and research are critical to curbing AMR and preventing resistant pathogens. Equitable access to treatments and international coordination are necessary to mitigate this global health crisis.

Access this article online

Website: www.cijmr.com

DOI: 10.58999/cijmr.v4i02.235

Keywords: Antimicrobial Resistance, Drug Resistance, Public Health, Sustainable Development Goals, Health Systems, Antimicrobial Stewardship

Introduction

AMR is one of the most urgent health challenges, affecting public health, healthcare systems, economies, and global development. This collection of studies looks at how AMR impacts society in many ways and presents innovative solutions to address the rising threat of drug-resistant pathogens.[1]

Governments are pivotal in combating AMR by implementing regulatory frameworks to monitor antibiotic use, funding research for alternative therapies, and ensuring equitable access to diagnostics and treatments.[1] Governments also play a critical role in raising public awareness about the dangers of antibiotic misuse through targeted campaigns and fostering international collaborations to strengthen surveillance networks.

The pharmaceutical and biotechnology sectors are instrumental in innovating new antibiotics, developing alternative therapies such as antimicrobial peptides, and creating rapid diagnostic tools.[2] These industries must work alongside policymakers to ensure affordable and widespread access to their innovations, addressing disparities in low- and middle-income countries.

HCWs are at the frontline of implementing antimicrobial stewardship (AMS) programs, educating patients about responsible antibiotic use, and promoting infection prevention and control (IPC) measures. Their efforts are critical in reducing the misuse of antibiotics and preventing the spread of resistant pathogens.[3]

An integrated effort among these stakeholders ensures a comprehensive approach to curbing AMR. Governments set the stage with regulations and funding, industries drive innovation, and HCWs operationalize these strategies in healthcare settings. Collaborative

Nursing & Midwifery Research Department, Hamad Medical Corporation, Doha 3050, Qatar.

Correspondence to: Kalpana Singh, Nursing & Midwifery Research Department, Hamad Medical Corporation, Doha 3050, Qatar. E-mail: KSingh1@hamad.qa

Submitted: 05/05/2025 Revision: 10/05/2025
Accepted: 15/05/2025 Published: 14/08/2025

How to cite this article: Singh K. Exploring the Societal Impact of Antimicrobial Resistance. Central India Journal of Medical Research. 2025;4(2):1-3.

action at all levels is essential to mitigate the societal and economic impact of AMR.

Evidence-Based Medical Strategies

This editorial emphasizes evidence-based approaches to mitigating AMR:

Antimicrobial stewardship (AMS)

AMS is a systematic approach aimed at optimizing antibiotic use to prevent the emergence of drug-resistant pathogens. AMS involves promoting judicious prescribing practices, ensuring that antibiotics are only used when necessary, and tailoring treatments based on accurate diagnoses. From a societal perspective, AMS reduces healthcare costs by minimizing hospital stays and preventing the need for expensive second-line therapies. Furthermore, AMS helps to preserve the effectiveness of existing antibiotics, benefiting both current and future generations by safeguarding global health infrastructure [4]. Effective AMS programs rely on collaboration among healthcare professionals, policymakers, and patients to create a culture of accountability and responsible antibiotic use.

Global action plans (GAPS) and National action plans (NAPS)

GAPs provide a unified framework for combating AMR at the international level, emphasizing collaboration across sectors and regions. They highlight the need to address AMR through a One Health approach, integrating human, animal, and environmental health. National Action Plans (NAPs) are tailored adaptations of GAPs designed to meet the specific needs of individual countries. By addressing unique societal, economic, and cultural contexts, NAPs ensure the equitable implementation of strategies. For instance, low- and middle-income countries may prioritize strengthening healthcare infrastructure and enhancing public awareness, while high-income countries may focus on advancing rapid diagnostic technologies and alternative therapies. Aligning NAPs with Sustainable Development Goals (SDGs), such as reducing inequalities (SDG 10) and promoting good health and well-being (SDG 3), ensures a comprehensive and inclusive approach to AMR mitigation.[1,4]

Alternative therapies

Advances in biotechnology, such as bacteriophage therapy and antimicrobial peptides, offer novel solutions for resistant infections. These therapies, supported by recent studies, reduce reliance on traditional antibiotics and address gaps in treating multidrug-resistant pathogens.[2]

Rapid diagnostics

Timely and precise identification of resistant pathogens is essential. Technologies such as AI-powered diagnostics and genomic sequencing enable targeted treatments, reducing the misuse of broad-spectrum antibiotics. These advancements help mitigate resistance growth and improve therapeutic outcomes.[5]

Infection prevention and control (IPC)

Strengthening IPC measures in healthcare settings, such as improved hygiene practices and vaccination programs, prevents the spread of resistant infections. Evidence shows that IPC programs significantly reduce infection rates and associated costs.[6]

Societal Implications of AMR

AMR's societal impact is profound:

Public health

Resistant infections result in longer hospital stays, higher mortality rates, and increased strain on healthcare systems.[6]

Economic costs

Rising treatment costs and productivity losses exacerbate poverty and inequality, especially in low- and middle-income countries.[4]

Surgical risks

AMR complicates procedures like organ transplants, reducing access to life-saving surgeries. Organ transplant patients, who require prolonged immunosuppressive therapies, are particularly vulnerable to resistant infections. These infections not only endanger individual patients but also burden society by increasing healthcare costs and straining transplant programs globally. This makes successful transplants less feasible, leading to higher morbidity and mortality rates and limiting access to critical life-saving interventions.[8]

Agricultural overuse

Antibiotic misuse in farming fosters resistance, with spillover effects on human health.[5]

Innovative Approaches to Collaboration

Addressing AMR requires a multifaceted collaboration among stakeholders that integrates cutting-edge technologies, community engagement, and tailored interventions:

Technological integration

Governments and industries must partner to scale AI-driven diagnostic tools and genomic sequencing

technologies, enabling early detection and precision treatment of resistant pathogens. Such technologies reduce dependency on broad-spectrum antibiotics and facilitate data-sharing platforms for global surveillance networks.[2,5]

Public-private partnerships (PPPs)

PPPs are essential to driving research and innovation. Industries can collaborate with academic institutions and governments to develop affordable alternative therapies, such as bacteriophage treatments, antimicrobial peptides, and vaccines targeting resistant pathogens.[6]

Community engagement and education

HCWs and policymakers should lead localized awareness campaigns to educate communities on responsible antibiotic use and infection prevention. Tailored strategies, such as incorporating cultural and linguistic contexts, ensure effective communication and long-term behavioral change.[4]

One health approach

Governments must institutionalize the One Health framework to address the interconnectedness of human, animal, and environmental health. This includes regulating antibiotic use in agriculture and promoting sustainable farming practices to reduce antibiotic runoff into ecosystems.[1]

Incentivizing innovation

Policymakers can offer financial incentives, such as tax credits and grants, to industries investing in novel antimicrobial therapies and diagnostic tools. These incentives foster innovation while ensuring equitable access to lifesaving technologies.[2]

Strengthening global partnerships

International organizations such as the WHO and FAO must enhance collaborative frameworks, focusing on resource-sharing and capacity-building in low- and middle-income countries. This ensures global alignment in combating AMR, particularly in resource-constrained settings.[3]

Conclusion

AMR transcends health, impacting societal well-being, healthcare systems, and global development. While some evidence-based strategies such as AMS programs and IPC measures have demonstrated success in reducing resistant infections, these editorial highlights novel approaches, including AI-powered rapid diagnostics and alternative therapies like bacteriophage treatment. Implementing tailored NAPs in conjunction with GAPs ensures that local needs are met, addressing global disparities effectively. Examples such as the integration of rapid diagnostic tools in high-income countries have reduced the misuse of antibiotics, while awareness campaigns in low- and middle-income countries have successfully curbed agricultural misuse of antibiotics. The road ahead calls for innovative collaboration across sectors, leveraging proven strategies and emerging technologies to protect public health. By emphasizing coordinated action, policy alignment, and technological innovation, we can mitigate AMR's impact and safeguard future generations. This comprehensive roadmap not only reduces healthcare burdens but also strengthens global health systems to achieve Sustainable Development Goals (SDGs) effectively.

References

1. Saroj SD. AMR policies and implementation issues: Developed vs developing countries. In: Antimicrobial Resistance. 1st ed. Boca Raton: CRC Press; 2022. p. 177–94. Available from: https://www.taylorfrancis.com/books/9781003313175/chapters/10.1201/9781003313175-8
2. Singh KS, Anand S, Dholpuria S, Sharma JK, Blankenfeldt W, Shouche Y. Antimicrobial resistance dynamics and the one-health strategy: a review. Environ Chem Lett. 2021 Aug;19(4):2995–3007. Available from: https://link.springer.com/10.1007/s10311-021-01238-3
3. Hillock, N. T., Merlin, T. L., Turnidge, J., & Karnon, J. (2022). Modelling the future clinical and economic burden of antimicrobial resistance: the feasibility and value of models to inform policy. *Applied Health Economics and Health Policy, 20*(4), 479-486. https://doi.org/10.1007/s40258-022-00728-x
4. Bhutta ZA, Reddy KS. Achieving equity in global health: So near and yet so far. JAMA. 2012 May 16;307(19). Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2012.4659
5. Yordanova R, Platikanova M, Hristova P. The use of antibiotics in food animals – a threat to human health. J IMAB - Annu Proceeding Sci Pap. 2024;30(2):5495–9. Available from: https://www.journal-imab-bg.org/issues-2024/issue2/vol30issue2p5495-5499.html
6. Charani E, Dlamini S, Koch A, Singh S, Hodes R, Laxminarayan R, et al. Power Relations in Optimisation of Therapies and Equity in Access to Antibiotics (PROTEA) Study: Investigating the intersection of socio-economic and cultural drivers on antimicrobial resistance (AMR) and its influence on healthcare access and health-providing behaviours in India and South Africa. Wellcome Open Res. 2024 Jul 24;9:400. Available from: https://wellcomeopenresearch.org/articles/9-400/v1
7. Song JH, Joo EJ. The crisis of antimicrobial resistance: current status and future strategies. J Korean Med Assoc. 2010;53(11):999. Available from: https://synapse.koreamed.org/DOIx.php?id=10.5124/jkma.2010.53.11.999
8. Kwon JH, Powderly WG. The post-antibiotic era is here. Science. 2021 Jul 30;373(6554):471. Available from: https://www.science.org/doi/10.1126/science.abl5997